Exchange: NASDAQ·Updated 07:59 PM EST

CAPR News

News
all
press releases
CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?
Sellas director Katherine Bach Kalin's purchased shares would be worth nearly $534,000 if retained, representing a 430% paper gain.
Stocktwits
CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?
Sellas director Katherine Bach Kalin's purchased shares would be worth nearly $534,000 if retained, representing a 430% paper gain.
Stocktwits
More News
Nvidia’s board is preparing to meet as soon as today to determine Jensen Huang’s future as the chipmaker’s chief executive, WSJ reported.
Stocktwits
The U.S. Food and Drug Administration is slated to decide on approving Capricor’s Deramiocel for the treatment of Duchenne muscular dystrophy by November 22.
Stocktwits
Oil prices recovered from two-month lows, with both Brent crude futures and WTI futures rising as attacks on shipping in and around the Strait of Hormuz kept supply concerns alive.
Stocktwits
The U.S. Food and Drug Administration is slated to decide on approving Deramiocel for the treatment of DMD by November 22.
Stocktwits
Analysts expect Capricor to post revenue of $10.4 million and a loss of $0.42 per share in Q3, according to Fiscal.ai data
Stocktwits
The U.S. Food and Drug Administration is slated to decide on approving Deramiocel for the treatment of DMD by November 22.
Stocktwits
Oil prices also edged higher as markets awaited Washington’s next move in the war in Iran.
Stocktwits
The FDA is slated to decide on approving Capricor’s drug for the treatment of Duchenne muscular dystrophy by November 22.
Stocktwits
November brings several closely watched FDA decisions, with Regeneron and its partner Alnylam’s therapy for generalized myasthenia gravis and Roche’s Gazyva for primary membranous nephropathy in the spotlight this week.
Stocktwits

Advertisement|Remove ads.